To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: 2025-2026 RSV Season Close Out Guidance
Date: May 1, 2026
As the Respiratory Syncytial Virus (RSV) season comes to an end, the Maine Immunization Program (MIP) is providing updated guidance and best practices for closing out the 2025-2026 RSV season for infants and young children.
Administration of either RSV monoclonal antibody products ended as of April 30, 2026, based on current surveillance indicating low levels of RSV activity in Maine.
Please ensure all administered doses of nirsevimab and clesrovimab have been entered into ImmPact and inventory has been reconciled to reflect quantity on hand.
Storage and Handling During Off-Season
Proper storage and handling of nirsevimab and clesrovimab is essential in maintaining the effectiveness of the product. Any inventory remaining after April 30, 2026, should continue to be stored appropriately and monitored until the next RSV season.
-
Pre-filled syringes should be stored refrigerated between 36°F to 46°F (2°C to 8°C).
-
Store in the original carton to protect from light until time of use.
-
Do not freeze or expose to heat.
-
Do not use either product beyond the expiration date printed on the label.
-
Label any remaining doses and keep away from other vaccines to help prevent vaccination errors.
Birthing Hospitals with RSV Inventory Only
Birthing hospitals that do not wish to continue storing RSV monoclonal antibody products through the end of the 2025-2026 RSV season, should contact MIP to coordinate a transfer of doses.
Provider sites may also transport to another VFC enrolled site to hold doses of nirsevimab or clesrovimab if space is an issue. Inventory and cold chain must be up to date for both provider sites in ImmPact prior to transport. Instructions for proper vaccine transport can be found here.
Considerations for the Fall 2026-2027 RSV Season
The following information is for consideration between health care providers and their patients, regarding the timing of RSV vaccination, given the extended 2026 RSV season:
-
Infants in their first RSV season who received either RSV monoclonal antibody in March or April, but who do not meet the high-risk criteria, would not be eligible to receive another dose in the second RSV season (starting in October) even if they are less than 8 months of age.
-
Infants who do not receive a dose of RSV vaccine in March or April would be able to get a dose during the fall months.
Thank you for your diligence and commitment throughout the RSV season to ensure that infants and young children in Maine have access to RSV prevention.
|
